S. 4583 · 118th Congress

Creating Hope Reauthorization Act of 2024

Introduced on Jun 18, 2024 by Robert P. Casey, Jr. (D-PA). 9 cosponsors, 4 of them from another party. Latest action (Jun 18, 2024): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Stage
Introduced
Introduced
Jun 18, 2024
Cosponsors
9
4 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.

Subjects

  • Child health
  • Drug safety, medical device, and laboratory regulation
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Robert P. Casey, Jr.D-PASponsor

Democrats · 5

Republicans · 4

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jun 18, 2024Introduced in Senate
  2. Jun 18, 2024 · SenateRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. STEALTH BIOTHERAPEUTICS INC.6 reports
    $390K reported (all issues)
  2. BIOTECHNOLOGY INNOVATION ORGANIZATION5 reports
    $3.1M reported (all issues)
  3. ACADIA PHARMACEUTICALS4 reports
    $730K reported (all issues)
  4. EVERYLIFE FOUNDATION FOR RARE DISEASES4 reports
    $100K reported (all issues)
  5. BIOMARIN PHARMACEUTICAL INC.3 reports
    $910K reported (all issues)
  6. Bayer Corporation (consolidated report)3 reports
    $6.2M reported (all issues)
  7. CHIESI USA, INC.3 reports
  8. CURE SMA3 reports
    $225K reported (all issues)
  9. Patients Rising Now3 reports
    $30K reported (all issues)
  10. Travere Therapeutics3 reports
    $360K reported (all issues)Federal contractor: TRAVERE THERAPEUTICS, INC.$323.9K in contracts, FY2026AI match · 100%
  11. bluebird bio, Inc.3 reports
    $120K reported (all issues)
  12. ALLIANCE FOR REGENERATIVE MEDICINE2 reports
    $350K reported (all issues)
  13. BRIDGEBIO PHARMA INC.2 reports
    $500K reported (all issues)
  14. Biotechnology Innovation Organization (BIO)2 reports
    $160K reported (all issues)
  15. IONIS PHARMACEUTICALS, INC.2 reports
    $160K reported (all issues)
  16. RARE DISEASE COMPANY COALITION2 reports
    $120K reported (all issues)
  17. Rocket Pharmaceuticals, Inc.2 reports
    $60K reported (all issues)
  18. SHIONOGI INC.2 reports
    $170K reported (all issues)Federal contractor: SHIONOGI INC$156.1M in contracts, FY2026AI match · 100%
  19. ULTRAGENYX PHARMACEUTICAL INC.2 reports
  20. Astria Therapeutics, Inc.1 report
    $40K reported (all issues)
  21. Epilepsy Foundation1 report
    $60K reported (all issues)
  22. Fulcrum Therapeutics1 report
    $60K reported (all issues)
  23. SOLENO THERAPEUTICS, INC.1 report
    $50K reported (all issues)

Reports filed in 2024, 2025.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.